Prophylactic therapy for migraine is prescribed to reduce migraine frequency, severity, and duration of attacks and to increase responsiveness of attacks to acute treatment. Generic oral AEDs (e.g., topiramate), beta blockers (e.g., propranolol), antidepressants (e.g., amitriptyline), and AbbVie’s Botox are historical mainstays, but an influx of novel CGRP-targeting injectable (Amgen/Novartis’s Aimovig, Teva’s Ajovy, Eli Lilly’s Emgality, and Lundbeck’s Vyepti) and oral (Pfizer’s Nurtec ODT and AbbVie’s Qulipta) prophylactic agents is transforming the paradigm. Although they target a common pathway, these novel agents differ meaningfully in their clinical profile, in addition to their route and frequency of administration; as such, they appeal differentially to patients and the various specialists prescribing prophylactic treatment (e.g., PCPs, neurologists). Understanding prescribing patterns and drivers is paramount for established agents competing for market share and for developers of emerging treatments.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.